MA45172B1 - Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées - Google Patents

Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Info

Publication number
MA45172B1
MA45172B1 MA45172A MA45172A MA45172B1 MA 45172 B1 MA45172 B1 MA 45172B1 MA 45172 A MA45172 A MA 45172A MA 45172 A MA45172 A MA 45172A MA 45172 B1 MA45172 B1 MA 45172B1
Authority
MA
Morocco
Prior art keywords
modified rna
formulations
polypeptides
rna encoding
encoding vegf
Prior art date
Application number
MA45172A
Other languages
English (en)
Other versions
MA45172A (fr
Inventor
Leif Karlsson Parinder
Danielson Regina Desirée Fritsche
Kenny Mikael Hansson
Li Ming Gan
Jonathan Clarke
Ann-Charlotte Eva Egnell
Kenneth Randall Chien
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA45172A publication Critical patent/MA45172A/fr
Publication of MA45172B1 publication Critical patent/MA45172B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'arn modifiées codant pour des polypeptides vegf-a et des formulations comprenant l'arn modifié. Des aspects de l'invention concernent en outre des préparations et des utilisations de formulations comprenant l'arn modifié dans le traitement de sujets souffrant de maladies sensibles à une thérapie par vegf-a.
MA45172A 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées MA45172B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346979P 2016-06-07 2016-06-07
US201662411091P 2016-10-21 2016-10-21
US201662432005P 2016-12-09 2016-12-09
PCT/US2017/036188 WO2017214175A1 (fr) 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Publications (2)

Publication Number Publication Date
MA45172A MA45172A (fr) 2019-04-10
MA45172B1 true MA45172B1 (fr) 2021-11-30

Family

ID=59270113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45172A MA45172B1 (fr) 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Country Status (25)

Country Link
US (1) US11866475B2 (fr)
EP (2) EP3464338B1 (fr)
JP (3) JP6859369B2 (fr)
KR (4) KR102552543B1 (fr)
CN (2) CN116606861A (fr)
AU (2) AU2017277277B2 (fr)
CA (1) CA3026500A1 (fr)
CY (1) CY1124667T1 (fr)
DK (1) DK3464338T3 (fr)
ES (1) ES2895421T3 (fr)
HR (1) HRP20211569T1 (fr)
HU (1) HUE056055T2 (fr)
IL (1) IL263370A (fr)
LT (1) LT3464338T (fr)
MA (1) MA45172B1 (fr)
MX (1) MX2018015110A (fr)
PL (1) PL3464338T3 (fr)
PT (1) PT3464338T (fr)
RS (1) RS62556B1 (fr)
RU (1) RU2756313C2 (fr)
SG (2) SG10202012175YA (fr)
SI (1) SI3464338T1 (fr)
SM (1) SMT202100586T1 (fr)
TW (2) TWI818375B (fr)
WO (1) WO2017214175A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606861A (zh) 2016-06-07 2023-08-18 摩登纳特斯有限公司 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途
US11628227B2 (en) * 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
SI3703658T1 (sl) 2017-10-31 2022-09-30 Astrazeneca Ab Lipidni nanodelci za dostavljanje spremenjene RNA, ki kodira polipeptid VEGF-A
WO2020227690A1 (fr) * 2019-05-08 2020-11-12 Modernatx, Inc. Procédés d'utilisation de nanoparticules lipidiques pour l'administration d'arn modifié codant pour un polypeptide vegf-a et compositions pharmaceutiques les comprenant
JP7345888B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023061985A2 (fr) * 2021-10-12 2023-04-20 Modernatx, Inc. Compositions comprenant un arn modifié codant pour vegf-a et procédés d'utilisation
WO2023084013A1 (fr) * 2021-11-12 2023-05-19 Modernatx, Inc. Compositions comprenant un arn modifié codant vegf-a et méthodes d'utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
AU2006211960A1 (en) 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
RU2497532C2 (ru) * 2008-12-03 2013-11-10 Эморсайт, Инк. Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
WO2011069529A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
EP2651445A2 (fr) 2010-12-16 2013-10-23 SPRNA GmbH Composition pharmaceutique à base d'arn qui comprend un métal alcalin en tant que contre-ion et formulé avec des dications
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP3460064B8 (fr) 2011-04-03 2024-03-20 The General Hospital Corporation d/b/a Massachusetts General Hospital Expression protéique efficace in vivo à l'aide d'arn modifié (mod-arn)
CA3018046A1 (fr) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Nucleoside, nucleotide, et compositions d'acide nucleique modifies
CN104968354A (zh) 2011-12-21 2015-10-07 现代治疗公司 增加器官或器官外植体的活力或寿命的方法
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
WO2014152211A1 (fr) * 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation et administration de compositions de nucléosides, de nucléotides, et d'acides nucléiques modifiés
KR102354389B1 (ko) * 2013-08-21 2022-01-20 큐어백 아게 Rna―암호화된 단백질의 발현을 증가시키는 방법
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
EP3247398A4 (fr) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Compositions de nanoparticules lipidiques
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
CN116606861A (zh) 2016-06-07 2023-08-18 摩登纳特斯有限公司 编码vegf-a多肽的经修饰的rna、配制品和关于它们的用途
WO2018104540A1 (fr) 2016-12-08 2018-06-14 Curevac Ag Arn pour la cicatrisation des plaies
MX389934B (es) 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
SI3703658T1 (sl) 2017-10-31 2022-09-30 Astrazeneca Ab Lipidni nanodelci za dostavljanje spremenjene RNA, ki kodira polipeptid VEGF-A
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法

Also Published As

Publication number Publication date
KR102376245B1 (ko) 2022-03-21
PL3464338T3 (pl) 2021-12-27
CN109790207A (zh) 2019-05-21
RU2756313C2 (ru) 2021-09-29
WO2017214175A1 (fr) 2017-12-14
US11866475B2 (en) 2024-01-09
ES2895421T3 (es) 2022-02-21
SI3464338T1 (sl) 2022-02-28
JP7167226B2 (ja) 2022-11-08
RS62556B1 (sr) 2021-12-31
EP3464338A1 (fr) 2019-04-10
US20200407411A1 (en) 2020-12-31
HUE056055T2 (hu) 2022-01-28
SG11201810816QA (en) 2018-12-28
RU2018147229A3 (fr) 2020-09-23
AU2017277277B2 (en) 2023-05-04
KR20230019505A (ko) 2023-02-08
CN116606861A (zh) 2023-08-18
EP3464338B1 (fr) 2021-07-21
JP6859369B2 (ja) 2021-04-14
JP2023011733A (ja) 2023-01-24
TWI818375B (zh) 2023-10-11
KR20230107891A (ko) 2023-07-18
CY1124667T1 (el) 2022-07-22
EP3971204A1 (fr) 2022-03-23
TW201808325A (zh) 2018-03-16
AU2023208200A1 (en) 2023-08-17
CA3026500A1 (fr) 2017-12-14
HRP20211569T1 (hr) 2022-01-21
TW202218670A (zh) 2022-05-16
DK3464338T3 (da) 2021-10-18
MA45172A (fr) 2019-04-10
KR102552543B1 (ko) 2023-07-06
TWI752036B (zh) 2022-01-11
KR102494499B1 (ko) 2023-01-31
KR20190039066A (ko) 2019-04-10
IL263370A (en) 2018-12-31
CN109790207B (zh) 2023-06-20
AU2017277277A1 (en) 2019-01-03
KR20220038819A (ko) 2022-03-29
JP2021100961A (ja) 2021-07-08
LT3464338T (lt) 2022-01-10
MX2018015110A (es) 2019-09-06
JP2019521976A (ja) 2019-08-08
SMT202100586T1 (it) 2021-11-12
PT3464338T (pt) 2021-10-19
RU2018147229A (ru) 2020-07-10
SG10202012175YA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MY196882A (en) Recombinant binding proteins and their use
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
MA38478A1 (fr) Anticorps anti-pac1 humains
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
EA201792047A1 (ru) Новые соединения
EA201890006A1 (ru) Применение экзосом для лечения болезни
PH12017501583B1 (en) Novel proteins specific for cd137
MA39342B2 (fr) Anticorps il -21
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
MX2024005705A (es) Composiciones de liquidos ionicos.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EP3492096A4 (fr) Composition pharmaceutique pour le traitement de maladies oculaires, contenant une protéine cas9 et un arn guide
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
EA201992688A1 (ru) Средства, пути применения и способы лечения
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MA38369B1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MX2021008126A (es) Vacuna de arnm.
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.